SEP 24, 2014 1:00 PM PDT

The VCNDD: CNS Drug Discovery in Academia

Speaker
  • Co-Director and Director of Medicinal Chemistry, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD)
    Biography
      Craig W. Lindsley, Ph.D. is the Co-Director and Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).  Craig graduated in 1992 from California State University, Chico with a B.S. in Chemistry, received his Ph.D. degree in Chemistry from the University of California, Santa Barbara (Lipshutz), in 1996, and pursued postdoctoral studies at Harvard University (Shair). In 2001, Craig accepted a position at Merck & Co where he pioneered, in positions of increasing responsibility, the development of allosteric ligands for Akt, mGlu5 and M1, providing critical proof-of-concept compounds that validated the mechanism of allosteric modulation and clinical candidates.  In 2006, Craig accepted an Associate Professor position in Pharmacology and Chemistry at Vanderbilt University, and promoted to Full Professor in 2009.  In that same year, Craig became the founding Editor-in-Chief of ACS Chemical Neuroscience and was also awarded the ASPET-Astellas Award for Translational Pharmacology.  In 2013, Craig was awarded the Portoghese Lectureship from the ACS MEDI division and the Journal of Medicinal Chemistry for impact in the field of medicinal chemistry, and in 2014, received the John J. Abel Award in Pharmacology from ASPET. Craig holds 40 issued US patents and has published over 300 manuscripts and another 140 published patent applications.  

    Abstract

    This lecture will provide an overview of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), focusing on how an Academic Drug Discovery Center was established and is maintained. I will discuss why we elected to focus on allosteric modulation of GPCRs and how we interact with corporate partners (both biotech and big Pharma) and the structure of licensing and sponsored research. Key to the success of the Center is an appreciation that there is no 'one size fits all' for collaborations with industry and biotech, and our Center has thus far formed seven unique collaborations. In this talk, I will discuss all of these, as well as the pros and cons of the different models. Finally, I will showcase an example from HTS to IND-enabling studies for a challenging target with a corporate partner that was successful due to the 'deep dive' into the basic science by our academic arm of the VCNDD.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    DEC 05, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 9:00 AM PST
    DATE: December 5, 2019TIME: 9:00am PST, 12:00pm EST Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues e...
    APR 30, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 30, 2020 8:00 AM PDT
    DATE:April 30, 2020 TIME: 8AM PT, 11AM ET, 4PM BST, 5PM CEST Cytokinesis is the physical separation of two cells that occurs after the completion of mitosis. The mechanism underlying it is v...
    Loading Comments...
    Show Resources